tiprankstipranks
pc:enh58

Enhanced Genomics

St Johns Innovation Centre, Cowley Road Unit 1, Jeffreys Building Cambridge , CB4 0DS, GB
https://enhancedgenomics.com/
Enhanced Genomics is a biotechnology company specializing in 3D multi-omics to identify genetically validated drug targets for complex genetic diseases. Utilizing a proprietary platform and cell type-specific atlas, the company translates disease-associated data into actionable insights, enhancing the probability of success in pharmaceutical development. Enhanced Genomics focuses on addressing unmet medical needs in common diseases, including autoimmune conditions, by developing effective therapies through strategic partnerships with pharma and biotech sectors.

Leadership & Board

Current Number of Employees18
Current LinkedIn Followers5,805

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$19M
Total Amount Raised$19M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$19M
Latest Funding Amount$19M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Employee Trend

Enhanced Genomics had 18 employees as of May 25, 2026. The number of employees decreased by 1 (5.26%) week-over-week.
18Latest Employee Count
1(-5.26%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Enhanced Genomics had 5,805 followers as of May 25, 2026. The number of followers increased by 22 (0.38%) week-over-week.
5,805Latest Followers Count
22(0.38%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 16, 2025
Series A
$19.00M

Investors

Investor Name
Funding Round
Series A
Series A
Series A

Related News and Analysis